Company: AEMD
Filing Date: 2025-06-26
Form Type: 10-K
Source: 0001683168-25-004780
Chunk: 2021

Company: AETHLON MEDICAL INC
Filing Date: 2025-06-26
Form: 10-K
Item: Item 8
Chunk 2021
---
 of common stock

    (7)
    Consist of 3,923 shares of common stock.

    (8)
    Consists of 6,208 shares of common stock.

    (9)
    Consists of
    2,552 shares subject to stock options that are currently exercisable or will be exercisable within 60 days of March 31,
    2025.

    (10)
    Consists of 3,569 shares
of common stock

Equity Compensation Plans

The following table sets forth information, as
of March 31, 2025, about our equity compensation plans in effect as of that date:

    Plan category 
    (a) Number of securities to be issued upon exercise of outstanding options, warrants and rights (1)  
    (b) Weighted-average exercise price of outstanding options, warrants and rights  
    (c) Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a)) 

    Equity compensation plans approved by security holders (2) 
     6,546  
    $130.52  
     390,950 

    Equity compensation plans not approved by security holders (3) 
     –  
     –  
     – 

    Totals 
     6,546  
    $130.52  
     390,950 

    (1)
    Net of equity instruments forfeited, exercised or expired.

    (2)
    Excludes RSU grants to our officers and directors during the fiscal year ended March 31, 2025, since all of the shares underlying the RSUs had been issued during that fiscal year and there were no outstanding RSUs as of March 31, 2025.

    (3)
    As of March 31, 2025, we did not have any equity compensation plans that were not approved by our stockholders.

 72 

Item 402(v) Pay Versus Performance

We
are providing the following information about the relationship between executive compensation actually paid and certain financial performance
of our company as required by Section 953(a) of the Dodd-Frank Wall Street Reform and Consumer Protection Act and Item 402(v) of Regulation
S-K. The disclosure included in this section is prescribed by SEC rules and does not necessarily align with how the Company or the Compensation
Committee view the link between the Company’s performance and named executive officer (“NEO